Home  /  Resource Library  /  Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium

Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium

Results of a study investigating CAR-T therapy brexucabtagene autoleucel for treatment of relapsed mantle cell lymphoma. (Abstract only)